Sreedhara Alavattam,Lukas C. Amler,Mark C. Benyunes,Emma L. Clark,Christina H. de Toledo Pelizon,Zephania W. Kwong Glover,Lada Mitchell,Jayantha Ratnayake,Graham A. Ross,Ru-Amir Walker
申请号：
US15058520
公开号：
US20160175438A1
申请日:
2016.03.02
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population； combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity； and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.
